MSTN and metabolic disease: Follistatin, a glycoprotein known to antagonize the actions of several members of the TGFβ family, such as myostatin and activin A [55], and contribute to metabolic disorders, has also been shown to promote skeletal muscle hypertrophy [56], and affect cartilage formation, postnatal bone metabolism, and fracture healing [57,58].